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[571 ABSTRACT 
Novel methods of retroviral-mediated gene transfer for the 
in vivo corporation and stable expression of eukaryotic or 
prokaryotic foreign genes in tissues of living animals is 
described. More specifically, methods of incorporating for- 
eign genes into mitotically active cells are disclosed. The 
constitutive and stable expression of E. coli P-galactosidase 
gene under the promoter control of the Moloney murine 
leukemia virus long terminal repeat is employed as a par- 
ticularly preferred embodiment, by way of example, estab- 
lishes the model upon which the incorporation of a foreign 
gene into a mitotically-active living eukaryotic tissue is 
based. 
Use of the described methods in therapeutic treatments for 
genetic diseases, such as those muscular degenerative dis- 
eases, is also presented. In muscle tissue, the described 
processes result in genetically-altered satellite cells which 
proliferate daughter myoblasts which preferentially fuse to 
form a single undamaged muscle fiber replacing damaged 
muscle tissue in a treated animal. The retroviral vector, by 
way of example, includes a dystrophin gene construct for 
use in treating muscular dystrophy. 
The present invention also comprises an experimental model 
utilizable in the study of the physiological regulation of 
skeletal muscle gene expression in intact animals. 
14 Claims, 2 Drawing Sheets 
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SATELLITE CELL PROLIFERATION IN 
ADULT SKELETAL MUSCLE 
The insertion of foreign genes or DNA into an organism’s 
genome has become a powerful tool in experimental biology 
during the past decade. This modification of genetic infor- 
The United States government may own rights in the mation has been attempted via the development of a variety 
present invention pursuant to NASA grant NAG2-239 5 of experimental protocols. Many experiments have trans- 
(F.W.B.), PHS grant AB19393 (F.W.B.1, and postdoctoral ferred genes into mammalian cells in culture and into newly 
training grant DK07520 (D.B.T.). fertilized mammalian eggs that then develop into an intact 
The present application is a continuation of U.S. Ser. No. animal. L~~~ commo,.,ly, have been performed 
07/479,065, filed Feb. 12, 1990, now abandoned. .^ wherein foreign DNA is inserted into the genome of cells of 
young or adult animals in situ. The insertion of foreign DNA 
into the genome of a cell or embryonic tissue has been 
I U  
BACKGROUND OF THE INVENTION 
1. Field of the Invention postulated to be applicable in the treatment of genetic 
The present invention relates to the field of molecular diseases in higher e*Wotes, PmiCularlY in h n a n s .  kkth- 
genetics and its use in the preparation of therapeutic agents 15 ods currently under extensive study in the manipulation of 
effective in vivo in adult tissue. More particularly, stem cells genes include in vitro DNA transfection techniques, in vivo 
are genetically modified in vivo and then function to induce whole cell injection (i.e., hematopoetic and myoblast cells), 
regeneration and repair of damaged tissue throughout the and in vivo as well as in vitro retroviral-mediated gene 
life span of an animal. More specifically, the present inven- transfer. ~ 
tion relates to the retroviral-mediated transfer of marker 20 
genes into adult tissue in which a mitotically-active state of 
The insertion of foreign genes into an organism’s genome 
thus presents a potentially revolutionary method for treating 
satellite cells has been induced. 
Additionally, the present invention relates to methods of 
treating genetically-transmitted diseases. The invention also 
relates to methods and therapeutic treatInentS for regener- 25 
sting damaged ~ ~ c l e  tissuey as a PmiCUlar method for 
muscle regeneration in Persons With r~~ScUlar  dystrophy is 
disclosed. 
genetic-defect tractable diseases in man. However, many of 
these genetic diseases remain to be more fully characterized 
before gene therapy can be used in their treatment. 
genetic-defect diseases identified in the literature include, by 
way of example, the various forms of muscular dystrophy 
(see Table l), diabetes, hemophilia and albinism. The vari- 
ous forms of muscular dystrophic diseases appear below. 
Some of the more fully characterized ecamples of 
2. Description of Related Art 
TABLE 1 
The Progressive Muscular Dystrophies 
Pattern of 
Muscular 
Type of Dystrophy ~ Age of Onset Involvement Special Features CELevel Inheritance 
Duchenne 
Becker 
Emery-Dreifuss 
Landouzy-Dejerine 
Scapulohumeral 
of Seitz 
Limb-girdle (Erb) 
von Graefe- 
Fuchs 
Oculophqngeal 
Infancy or early 
childhood 
Childhood, 
adolescence, 
or early adult 
Childhood, 
adolescence 
Late Childhood, 
adolescence 
girdle-late 
Childhood, 
or adult 
Childhood, 
adolescence, 
sometimes 
adult 
Childhood, 
adolescence 
Middle or late 
adult 
Pelvifemod, 
later pectoral 
girdle 
Pelvifemoral, 
later pectoral 
girdle 
Humeroperoneal 
Facioscapulo- 
humera pelvic 
normal 
Spinal and 
humeral, later 
pelvic girdle 
girdle-late 
Pectoral or pelvic 
or both 
ocular (sparing 
pupils); later 
facial and other 
muscles (slight) 
Levators of lids; 
other ocular- 
~ 
Hypemophy- 
pseudohyper- 
trophy; cardiac 
involvement; 
mental retardation 
cardiac 
involvement, 
sight; 
mentation 
normal 
Contractures 
posterior neck 
and biceps 
muscles 
Heart normal, 
mentation 
Cardiomyopathy 
Heart usually 
normal, 
mentation 
normal 
Kearns-Sap 
group have 
retinitis 
pigmentosa 
heart block, 
stunting of 
growth, and 
ovarian 
dysgenesis 
High 
~ 
Moderate 
Moderate 
~ 
Slight to 
moderate 
Slight to 
moderate 
Slight to 
moderate 
Slight to 
moderate 
Slight to 
normal 
X-linked 
recessive 
X-linked 
recessive 
X-linked 
recessive 
Dominant 
Dominant 
Variable, 
recessive, 
or dominant 
Dominant; 
Kearne-Sayre 
recessive 
Dominant 
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TABLE I -continued 
The Progressive Muscular Dystrophies 
Pattern of 
Muscular 
Type of Dystrophy Age of Onset Involvement Special Features CK Level Inheritance 
P h W W a l  
muscles later 
Myotonic Infancy, Ocular, facial, Cataracts, Slight to Dominant 
(Steinert) childhood, Stemomastoid, testicular normal 
adult forearm, aaophy 
peroneal 
pelvic girdles, retardation, moderate or recessive 
or difFuse arthrogryposis 
Congenital Birth, Infancy Pectoral and Mental Slight to Dominant 
Among the many genetic diseases described, the muscle 
degenerative, or muscular dystrophy-causing diseases, have 
experienced significant recent technological advances. For 
example, the muscular dystrophies have been traced to 
particular gene defects, the elucidation of which has expe- 
rienced particularly significant scientific breakthroughs in 
terms of genetic molecular characterization. The most 
widely known of the muscular dystrophies are Duchenne’s 
muscular dystrophy and the less severe Becker muscular 
dystrophy. Both of these genetic diseases are characterized 
by an inability of the muscle to produce dystrophin, which 
is a muscle protein. This defect is an x-linked recessive 
disease potentially caused by a defect in the dystrophin gene. 
The dystrophin gene has most recently been established as 
having a close relative gene on human chromosome 624. 
Prior studies have attempted the use of foreign normal 
myoblast injection as a form of gene product replacement. 
For example, foreign myoblasts containing a normal dys- 
trophin gene have been injected into dystrophic tissue to 
invoke the expression of the dystrophin protein in the 
muscle tissue. However, this method presents the inherent 
risk of immune rejection, as well as the necessity of injection 
at multiple, probably closely-spaced sitesz3. Additionally, 
injection at multiple sites is necessary with such a therapy 
because dystrophin, like other muscle proteins, tends to 
remain localized within a single fiber, close to the nuclei 
from which it was derived. An additional limitation of 
currently practiced myoblast-injection techniques is the low 
fusion rate of implanted myoblasts into normal host muscle 
tissues. 
Muscle tissue is characterized by the presence of satellite 
cells, which are located between the basal lamina and the 
sarcolemma of the skeletal muscle fibers. Satellite cells in 
skeletal muscle are dormant stem cells which are present 
outside the muscle fibers in an adult skeletal muscle. Each 
of these inactive stem cells can either proliferate into many 
satellite cells or mature into an embryonic myoblast upon 
the appropriate stimulation. 
By way of example, satellite cells of the muscle have been 
shown to become stimulated to replicate by muscle damage 
(Allbrook, 1981; Carlson et al., 1983). It is also possible that 
strenuous exercise may stimulate cells to become mitotically 
active and to repli~ate.’~ Chemical damage via bupivacaine 
injection into mammalian skeletal muscle cells has been 
shown to result in rapid recovery of the tissue showing 
maximum proliferative capacity of satellite cells 36-48 
hours following damage6.14. As stem cells, satellite cells 
function to supply myonuclei to growing fibers in immature 
animals as well as to provide myogenic cells for muscle 
regeneration and repair throughout the life of the animal. 
Several laboratories have published protocols by which 
the hematopoietic cells of mice have had new genes intro- 
duced with retroviral vectors ex vivo, with subsequent 
2o reintroduction of the treated cells into the bone marrow in 
vivozz. In this system, marrow cells are obtained from a 
donor and incubated with a monolayer of vector-generating 
producer cells. Since marrow cells, unlike the producer cells, 
do not attach to the culture disk, they are easily recovered 
25 after co-cultivation. The hematopoietic cells are then intro- 
duced into a recipient animal by intravenous injection. 
Space in the hematopoietic system to receive the vector- 
treated marrow must be made usually by lethally irradiating 
the recipient. While this technique has been widely used 
30 experimentally, its use in humans is limited by the recurrent 
risk of host immune rejection, as current studies on muscle 
were performed on mdx (immunosuppressed) animalsz3. 
Additionally, low proportion of cells incorporate the normal 
myoblast dystrophin gene in myoblast transfer procedures. 
35 Moreover, multiple injections of myoblasts are typically 
required to achieve proper dispersion of the myoblasts in 
situ. 
A need thus remains in the art for the development of a 
4o therapeutic system which minimizes or eliminates host 
immune response, perhaps through the development of an 
entirely in vivo vector-induced, host cell gene incorporation 
process. However, technical difficulties in the manipulation 
of genomes from organisms both in achieving the initial 
45 incorporation of the desired gene by the host cells as well 
known as achieving expression of those genes in the host 
have limited techniques of direct incorporation of a gene 
without a “carrier” cell into damaged tissue in vivo. DNA 
transfection and retroviral mediated gene incorporation are 
5o two methods of such a “direct gene” incorporation which 
eliminates the need for a “carrier” cell. 
The treatment of genetically-related diseases with tech- 
niques as DNA transfection has thus far, unfortunately, not 
met with great success. In DNA transfection, DNA (presum- 
55 ably which includes a non-defective counterpart of the 
defective gene) is introduced into cells in culture as part of 
a coprecipitate with calcium phosphate or dextran sulfate.’ 
A successful result is a viable cell containing one to many 
copies of the new gene which continuously expresses the 
While several limitations exist in this system, the most 
significant limitation is that it is a very inefficient means of 
transferring genes into mammalian cells. For example, only 
one in a thousand cells (more typically, one cell in a million) 
65 will incorporate the newly transformed gene. Additionally, 
not all cultured cell lines are susceptible to this method of 
gene transfer. For example, while the stem cells located in 
60 new genetic information. 
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bone marrow are typically susceptible to this method of gene tem. Technical difficulties still exist in the use of retroviral 
transfer, they are present only as a small fraction (less than vectors for gene transfer in large animals (i.e., humans), such 
one cell in a thousand) of the total nucleated cells of the as in the efficiency of infection of pluripotent stem cells and 
tissue. Another limitation is that it is an ex vivo technique. in the long-term stability of expressed genes. Moreover, the 
This method is therefore inefficient as only a small 5 use of retroviral-mediated gene transfer is limited by the size 
population of cells incorporate the desired gene, failing to of the gene constructs which the virus is able to carry. For 
accomplish gene delivery to a large fraction of a target cell example, genes having more than 1400 base pairs have been 
population. Even if the technical difficulties of gene incor- found to be too large for common vectors. Such results in 
poration overcome, a second obstacle to the effective difficulties in replacing proteins, either for functional studies 
employment of this technique in the higher eukaryotes and 10 or in gene therapy experiments, which involve genes of this 
mammals which has not yet been solved in being able to size. 
attain proper expression of successfully incorporated genes In the development of an efficient retroviral gene transfer 
by the host. system, two parameters must be optimized. First is the 
Retroviral-mediated gene transfer (ix., the use of retro- capacity to infect a large proportion of the target cells, a 
viruses to deliver genes into cells) is an alternative gene 15 property dependent at least in part on the ability to generate 
transfer technology which has met with a limited, yet a high concentration (or titer) of recombinant virus. Second 
improved, success in host genome incorporation rates. Using is the capacity to have the gene expressed properly in the 
this technique, it is now possible to insert a gene into a host. 
retroviral vector to obtain a recombinant virus, and then An intense need exists in the art of molecular biology to 
infect target cells with the retrovirus (Which includes a *O either circumvent the limitations ofretroviral-mediated gene 
particular gene of interest) and achieve the expression ofthe transfer (gene size, gene incorporation ratio in target cells) 
foreign gene by the host cell's chromosomes. Retroviruses if retroviral vectors are to used in the medical treatment 
are RNA v h s e s ,  that is, the viral genes are encoded in an of genetic disease in humans. Additionally, the need for an 
RNA ~ o l e c u l e  rather than in a DNA molecule. All RNA efficient gene transfer system is desirable for its usefulness 
hmor  viruses are n ~ m b e r s  of the retrovirus family, but not 25 to basic research, as well as being an absolute prerequisite 
all retroviruses are oncogenic or even pathogenic. for application to human therapy. lo 
In retroviral-mediated gene transfer, the viral RNA is first The innovative development of gene transfer technology 
converted to DNA when an RNA virus penetrates a cell. If to improve target cell incorporation ratio while achieving 
the Cell penetrated is a replicating cell mitotically successful and acceptable amounts of gene expression in the 
active), the DNA will enter the nucleus and integrate into a 30 host, while eliminating host immme-response problems, 
chromosome. This integrated DNA becomes indistinguish- would revolutionize currently practiced methods of treating 
able as far as the cell is concerned from any other cellular genetically-induced maladies, especially those muscle 
gene. It is from this integrated form, that the Viral genes *e degenerative diseases which have escaped human interven- 
expressed. In this process, integration of the viral genome tion over the years. 
into the cell's chromosome is an essential part of its repli- 35 
cation. However, RNA retroviruses only insert their genome 
into mitotically active cells; thus making it highly unlikely 
that an RNA retrovirus would infect a mature myonucleus. The present invention presents a surprisingly effective and 
Thus7 O d Y  immature animal tissues have been used eXPeri- novel in vivo method of expressing foreign genes in an adult 
m e n a y  With n%rOViral-m?&ited gene transfer systems 40 eukaryotic tissue. This method accomplishes the incorpora- 
with much improvement of gene-incorporation rates. tion of a foreign gene of interest using a retroviral-mediated 
Retroviral mediated gene transfer remains a relatively gene transfer system wherein the target tissue is first treated 
inefficient gene transfer system for adult tissues owing to so as to induce a mitotically-active state in the cells of the 
low gene incorporation rates of target cells. It would there- 45 target tissue. 
fore only be by means of a highly efficient retroviral vector The present inventive method also presents an amazingly 
system that genetic maniPUlatiOn Of totipotent Stem Cells accurate and simple technique applicable to the study of 
would b ~ o m e  practical, as currently practiced methods of eukaryotic tissue regeneration, especially the regeneration of 
retroviral-gene transfer Provide only a Small fraction of muscle tissue. For example, with the presently disclosed 
genetically-altered cell components. 50 innovative retroviral gene transfer system, Applicants have 
A number of procedures are known to artificially induce been able to reveal for the first time two important aspects 
a mitotically-active state in a cell population. For example, of the cell biology of the muscle. First, that in damaged 
e~ercise, '~ tissue traumq6 chemical injection:' and radia- muscle, a satellite cell directs its daughter myoblasts almost 
tiongS3' have been shown to make tissue or cells in culture exclusively to a single regenerating fiber. Second, Appli- 
mitotically active. Many pharmaceutical agents (especially 55 cants' studies show that the apparent diffusion domain of a 
anesthetics, such as MarcaineB) have been found to destroy myonucleus overlaps several adjoining myonuclei, confirm- 
or damage muscle fibers." For example, it has been found ing the possibility of internuclear communication of factors 
that when bupivacaine (a local anesthetic) is injected into that may regulate gene expression in tissue, particularly that 
skeletal muscle, existing muscle fibers (including myonu- in muscle tissue. 
Clei) are In its broadest embodiment, the present invention com- 
cells in these tissues are left undamaged. prises a method for the in vivo incorporation of a foreign 
Despite developments in retroviral-mediated gene trans- gene into an adult tissue comprising infecting a mitotically- 
fer and studies regarding the in vitro and in vivo induction active cell in the living tissue with a retroviral vector. The 
of mitotically active states in certain cell populations, the retroviral vector of the present invention most preferably 
many unknown aspects of the structure and function of 65 comprises a replication deficient retrovirus and a foreign 
retroviruses have prevented the combination of these advan- gene. In one preferred embodiment of the claimed method, 
tages in the development of an efficient gene-transfer sys- the foreign gene of the retroviral vector is a prokaryotic 
SUMMARY OF THE INVENTION 
CuriOuSlY, however, the satellite 60 
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foreign gene. This prokaryotic foreign gene is in one appli- of interest in the genome of the mitotically-active cells of the 
cation of the invention, the P-galactosidase gene of E. coli. eukaryotic tissue. Most preferably, the retroviral vector is 
In still another embodiment of the claimed method, the replication deficient, and the gene of interest comprises a 
foreign gene of the retroviral vector is a eukaryotic gene. gene encoding an enzyme or protein which is complemen- 
Most preferably, when the foreign gene is a eukaryotic 5 tary to the deficiency or supplies the product of a defective 
foreign gene, the gene is a gene encoding dystrophin protein, gene in the host tissue being treated. 
or dystrophin gene, or a gene encoding insulin, or an insulin The gene of interest in one particularly preferred embodi- 
gene. Of these, the eukaryotic dYstroPhin gene is most ment of the described method comprises a prokaryotic 
Preferred. The dYstroPhin gene is in a nm3fied form as a foreign gene. In such a preferred embodiment, the prokary- 
dYstroPhin gene construct, which is Significantly smaller 10 otic foreign gene is a P-galactosidase gene. The gene of 
than the naturally occurring dYstroPhin gene. such is Pro- interest in still another particularly preferred embodiment of 
vided in order to allow the containment of the dystrophin the described method is a eukaryotic foreign gene. Preferred 
gene construct in a single retroviral vector. embodiments of the disclosed methods which include a 
In that the present methods allow for the incorporation of eukaryotic foreign gene are further defined as comprising a 
a single gene in a living tissue, particularly muscle tissue, the 15 eukaryotic gene such as an insulin gene, a dystrophin gene 
present invention allows for the follow-up study of the effect or a spectrin gene, or phenotypically sufficient fragments or 
of the in vivo specifically-altered genome on tissue function constructs thereof. Thus, in one particularly preferred 
resultant from the incorporation of a particular foreign gene. embodiment, the gene of interest is a dystrophin eukaryotic 
Additionally, the study of the control of gene expression in gene construct which is a modified dystrophin gene having 
tissues so genetically altered is also facilitated. 
Foreign gene expression in intact adult animals is In that the present methods may employ any eukaryotic 
achieved with the present invention through the efficient gene of interest in the retroviral vector, the described meth- 
incorporation of the foreign gene into the genome of the ods also comprise a method of gene therapy. As a method of 
target tissue or cells thereof. For this purpose, a retrovirus gene therapy, a particular defective gene in a eukaryotic 
which is replication deficient is employed, which includes a 25 tissue is replaced or substituted in vivo by a complementary 
gene encoding a desired gene product. In that the present non-defective gene in the cells of the eukaryotic tissue. In 
invention encompasses a method of gene incorporation, a such an embodiment, the present method of gene therapy for 
method of gene therapy for the replacement of a defective or the replacement of a defective gene in a eukaryotic tissue 
deficient gene is also disclosed. The gene which is to be Comprises: inducing a mitotically-active state in the eukary- 
incorporated by the target cells in this method encodes a 30 otic tissue to produce mitotically-active cells; preparing a 
product which supplies or is complementary to a particular retroviral vector comprising a gene complementary to the 
genetic deficiency present in the animal. defective gene in the eukaryotic tissue; and exposing the 
An object of the present invention is to eliminate the IllkOtiCally-aCtiVe Cells to the retrOVkd Vector for a time 
problem of immune response attendant many forms of gene 35 Period sufficient to allow the incorporation of the gene of 
transfer. Appficantsi method of incorporating a single for- interest in the eukaryotic cell, wherein incorporation Of the 
e i p  gene into eukaryotic cells completely in vivo, employ- gene of interest replaces the defective gene in the cells of the 
ing only a retrovkal vector, effectively eliminates the risk eukaryotic tissue. In a most preferred embodiment of this 
associated with immune rejection inherent to other tech- method, the gene complementary to the defective gene is a 
niques involving whole cell (e.g., myoblast) injection. eukaryotic gene, such as the dystrophin gene for the treat- 
complementation and repair totally in vivo, as compared to As a method for treating a genetic disease in a eukaryote, 
other techniques which require ex vivo vector transforma- the invention comprises incorporating a complementary 
tion of donor or recipient cells prior to treatment of the gene to a genetic deficiency in a stem Cell of the eukaryote, 
diseased or damaged tissue (i.e., donor myoblast retroviral 45 wherein incorporation of the complementary gene corn- 
infection and recipient injection of transformed myoblasts). PriSeS the Steps Of: inducing a mitotically-active state in the 
Pursuant thereto, the present invention features the advan- cells of the eukaryote to form a mitoticallY-active PrePara- 
tage over prior methods of avoiding host immune rejection tion of eukaryotic stem Cells; Preparing a retroviral vector 
of vector-transformed cells. While this obstacle does not comprising a eukaryotic gene complementary to the genetic 
exist when host autologous cells are used as the vehicle of 50 deficiency in the Cells ofthe eukaryote; exposing the mitoti- 
gene transformation, sufficient host autologous cells may not CallY-active Preparation of eukaryotic Stem cells to the 
be available for genetic therapy prior to their reintroduction retrOViral Vector; and incubating the retroviral vector with 
into the host. Limitations of the system attendant the avail- the mitotically-active preparation Of eUkaryOtiC Cells a time 
ability of a sufficient population of the host cells (as the Period sufficient to allow incoWration of the ComPlemen- 
transforming agent) are eliminated by doing away with the 55 t W  gene in the eukaryotic Stem cell. In this manner, the 
need for extraction and genetic manipulation of the trans- deficiency in the eukaryotic genome is eliminated. 
forming cells. The risk of potential damage from manipu- Most preferably, the eukaryotic cell described in the 
lation of the transforming agent (i.e. host cells) is also present methods include totipotent eukaryotic cells, such as 
eliminated. a stem cell (Le., muscle satellite cells, hematopoietic stem 
A preferred embodiment of the presently described 60 cells (in bone mm0w)’3, dark basal keratinocYtes31). As 
method for incorporating a foreign gene into an adult used in the present application, the term “totipotent” relates 
eukaryotic tissue completely in vivo comprises: inducing a to a cell which is capable of differentiating into an entire 
mitotically-active state in an adult eukaryotic tissue to Organism or into a part of an organism, such as a cell which 
produce mitotically active eukaryotic cells; preparing a is capable of generating or differentiating to form a particu- 
retroviral vector comprising a gene of interest; and exposing 65 lar tissue (i.e., muscle, skin, heart, brain, uterus, testis, 
the mitotically-active cells to the retroviral vector for a time blood). 
period sufficient to allow genetic incorporation of the gene The eukaryote described in the present invention includes 
20 between 7,000-10,000 base pairs. 
The presently disclosed accomplish genetic 40 ment of animals with degenerative muscle disease. 
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all organisms comprising cells which contain a membrane- 
bound nucleus. In particularly preferred embodiments of the 
described methods, the eukaryotic tissue described in rela- 
tion to the disclosed methods is human tissue, rat tissue or 
mouse tissue. 
In the more preferred embodiments of the described 
methods, a mitotically-active state in a living eukaryotic cell 
or tissue comprises inducing cellular-repair mechanisms in 
the cell or tissue. Thus, the induction of a mitotically-active 
state comprises discomposing the tissue, exposing the cell to 
radiation, or administering a pharmaceutical chemical agent. 
As used in this application, the term discompose relates to 
any change in the normal resting state or non-mitotically 
active state of a eukaryotic cell culture or tissue, particularly 
that of a eukaryotic tissue. By way of example, discompo- 
sition of a tissue may be accomplished through vigorous 
exercise stimulation’, agitation, surgical intrusion or other 
trauma of the tissue or cell culture. 
The use of chemicals to induce a mitotically-active state 
in the cell (Le., in cell culture) or tissue described includes 
the administration of any of a variety of pharmaceutical 
agents. By way of example, the pharmaceutical agents 
capable of inducing a mitotically-active state in vitro or in 
vivo include bupivacaine, collagenase, dexamethasone, 
fibroblast growth factor, and any other reagent capable of 
inducing a mitotically-active state in a eukaryotic tissue or 
a eukaryotic cell. 
The retroviral vector is a retrovirus (RNA virus) which is 
replication deficient or replication incompetent. That is to 
say, the retrovirus lacks one or more of the replication genes, 
gag (group-specific antigen), pol (polymerase) or env (enve- 
lope) protein encoding genes. 
The gene therapy of the present invention comprises a 
method by which any of a variety of genetic diseases may be 
eliminated. The invention thus comprises a method of treat- 
ing genetic disease. Such is accomplished through the suc- 
cessful incorporation of a particular complementary gene or 
part of a complimentary gene in the genome of totipotent 
cells of the diseased organism, thereby facilitating the pro- 
duction of cells in the diseased host with similarly corrected 
genomes. By way of example, genetic diseases which may 
be treated employing the described methods include diabe- 
tes, albinism, and the various forms of muscular dystrophy. 
However, any recessive gene is hypothesized to be treatable 
employing the described methods of gene transfer and gene 
replacement. 
In a most preferred embodiment, a method for treating the 
genetic disease of muscular dystrophy is described. Muscu- 
lar dystrophy is a genetic disease characterized by a defec- 
tive gene encoding the muscle protein, dystrophin. In this 
particular embodiment of the invention, the gene of interest 
would be a part of the dystrophin gene (i.e., a dystrophin 
gene construct) which encodes a part, segment or fragment 
of the dystrophin protein, this particular protein segment 
supplying a sufficient part of the native dystrophin protein to 
protect the eukaryotic tissue from all but only the mildest 
phenotypic manifestation of muscle degeneration. This par- 
ticular dystrophin gene fragment is described by England et 
aLZ0 
The spectrin gene, which encodes a muscle protein simi- 
lar to dystrophin, is also hypothesized to be efective in the 
methods described herein for the treatment of muscular 
dystrophy. More particularly, a retroviral vector which 
includes a spectrin gene or a fragment of the spectrin gene 
may be effective in treating muscular dystrophy through the 
injection of such a retroviral vector into a eukaryotic tissue, 
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the eukaryotic tissue being treated so as to induce a mitoti- 
cally active state therein. Various methods for inducing such 
a mitotically active state are as otherwise described herein 
(radiation, trauma, exercise, chemical injection]. 
The retroviral vector in one preferred embodiment of the 
present invention would include a dystrophin gene construct 
which encodes a particular dystrophin protein fragment 
which is effective to halt massive or significant muscle 
degeneration, as well as to regenerate already damaged 
muscle tissue. In a most preferred embodiment of the 
invention for the treatment of muscular dystrophy, the 
retroviral vector includes a dystrophin gene construct com- 
prising between 7,000-10,OOO base pairs. In an even more 
preferred embodiment, the dystrophin gene construct com- 
prises about 9,000 base pairs of the native dystrophic gene. 
This dystrophin gene construct encodes a protein having a 
relative molecular weight of about 200,000 K. 
As a method of treating muscular dystrophy in a human 
or other eukaryotic organism, the present invention in a most 
preferred embodiment comprises the initial induction of a 
mitotically-active state in the tissue of the eukaryote through 
the intramuscular administration of bupivacaine to the skel- 
etal muscle tissue. The retroviral vector of this particular 
embodiment of the invention comprises a replication defec- 
tive murine leukemia virus. Most preferably, the murine 
leukemia virus comprises AKR, Moloney or Friend leuke- 
mia virus. However, most preferably, the retroviral vector 
comprises the replication defective Moloney murine leuke- 
mia virus. 
In still another embodiment of the present invention, the 
retroviral vector comprises a prokaryotic gene, such as a 
P-galactosidase gene, wherein the P-galactosidase gene is 
under the control of the retroviral 5’ long terminal repeat 
promoter region. More particularly, the P-galactosidase gene 
is under the control of a constitutive promote?. A method 
for monitoring gene expression in tissue is thereby provided 
(i.e., focal and diffuse expression). For example, as 
employed to infect muscle tissue in eukaryotes, Applicants 
propose that the use of such a vector system would track 
regenerating and fully recovered muscle fibers, in that 
regenerating and fully recovered muscle fibers would 
express the P-galactosidase gene product if the infected 
satellite cells gave rise to viable myoblasts. 
The disclosed methods are not to be limited to treatment 
of muscular degenerative diseases. For example, the gene of 
interest in the present invention may comprise any gene or 
part of any gene which complements a deficiency in the 
animal being treated. However, length of the gene of inter- 
est, or the coding region thereof, is preferably less than 
14,000 base pairs so as to facilitate the inclusion of the 
particular gene in a single retrovirus. 
Use of the presently described methods to stimulate stem 
cell proliferation allows the transformation of the genome 
of, in one particular embodiment, skeletal muscle satellite 
cells, resulting in the production of genetically-corrected 
myoblasts. These myoblasts then become the non-defective 
myonuclei of newly formed and non-defective muscle 
fibers. As will be appreciated, the invention in such an 
application comprises a method for regenerating muscle 
tissue. I n  a most preferred embodiment, this technique 
comprises a method of treating degenerated dystrophic 
muscle tissue. In this preferred embodiment, the regenera- 
tion of dystrophic muscular tissue, characteristic of such 
diseases as Duchenne’s muscular dystrophy and Becker 
muscular dystrophy, is specifically envisioned. 
As a therapeutic treatment for muscular dystrophy, Appli- 
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cants have found that the technique of stimulating stem cell 
proliferation to allow retroviral-mediated gene transfer is 
generally applicable to all eukaryotic tissues. Potential target 
cell populations for use with the present methods are char- 
acterized by the presence of stem cells. By way of example, 
tissues expected to be susceptible to the described treatments 
and methods are those tissues which include stem cells. By 
way of example, these stem-cell containing tissues include 
those tissues of the uterus, skeletal muscle, liver, kidney, 
blood, alimentary epithelium, testes, skin and gastrointesti- 
nal tissue. The stem cells of muscle tissue are the satellite 
cells. In the described methods, the stem cells &e., satellite 
cells) in muscle tissue are the cells which are infected with 
the retroviral vector to facilitate incorporation of the eukary- 
otic gene of interest in the satellite cell itself. These satellite 
cells may then function to supply myonuclei to growing 
fibers in immature animals and to provide myogenic cells for 
muscle regeneration and repair throughout the life of an 
animal. 
In that any of the methods described in the present 
application may be used in vivo, the retroviral vector may be 
further defined as comprising a retroviral vector conjugated 
to a protein. Such may be accomplished by methods well 
known to those of skill in the art, and will function to 
enhance the targeting of the vector to particular populations 
of target cells. 
The following abbreviations are used throughout the 
Specification: 
CFW=colony forming units 
ug=microgram 
EGTA=methylene glycol tetraacetic acid 
k b e t a  
um=micromolar 
P-galactosidasebeta-galactosidase (EC 3.2.1.23) 
MoLV=Moloney murine leukemia virus 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1-P-galactosidase expression in soleus muscle sec- 
tions. 24-48 hours after muscle damage the bupivacaine- 
damaged muscle and undamaged contralateral muscle were 
injected with 0.3 ml of the retrovirus carrying the p-galac- 
tosidase gene (2x105 CFU/ml). The animals were then 
housed in a biohazard facility for one week or four weeks. 
16 um frozen sections were stained for P-galactosidase 
activity using the method of Dannenberg and Suga’ to 
produce a distinct indigo blue precipitate. (A) Cross-section. 
Diffuse P-galactosidase activity occurs within the circum- 
ference of the fibers with adjacent fibers occasionally exhib- 
iting less intense staining. (B) Cross-section. More focal 
staining is often observed associated with the sarcolemma. 
(C) Longitudinal section. Diffuse P-galactosidase activity 
occurs uniformly over many nuclear domains. (D) Longi- 
tudinal section. Focal activity along the length of a fiber. The 
magnifications in all panels are identical; the length bar in 
(D) represents 10 um. 
DETAILED DESCRIPTION OF PREFERRED 
EMBODIMENTS 
The inventions of the present disclosure relate generally 
to gene transfer systems in eukaryotic cells and tissues. The 
practice of the invention provides an improved transfer 
system for eukaryotic and prokaryotic genes surprisingly 
improved over other practiced gene-transfer systems. For 
example, improvements of the present system include an 
12 
enhanced gene incorporation rate in a target cell population, 
successful target cell expression of the host-incorporated 
foreign gene, and elimination of host-immune rejection 
response. These methods of gene transfer are effected 
through the induction of a mitotically-active state in a target 
cell population prior to exposure to a retroviral vector. Target 
cells thus become receptive to retroviral gene insertion, thus 
greatly enhancing the rate of gene incorporation. Use of the 
direct in vivo injection of a retroviral vector eliminates the 
risk of host-immune response existent in 37 carrier cell” 
type gene transfer systems (ix., in vitro myoblast modifi- 
cation and subsequent in vivo injection). 
It is desirable that the retrovirus employed be replication 
deficient and be a murine leukemia virus. In most preferred 
15 embodiments of the invention, the retrovirus is an AKR, 
Moloney or Friend murine leukemia virus. Moreover, it is 
particularly desirable that the retrovirus include a particular 
gene of interest which is complementary to or provides a 
suitable substitute for a defective or deficient gene in the 
20 target cell population or tissue. 
In a most preferred use of the described invention, a 
method for the in vivo incorporation of a foreign gene into 
an adult tissue is described comprising infecting a mitoti- 
cally-active cell in the adult tissue with a retroviral vector. 
25 The retroviral vector in such a preferred embodiment com- 
prises a eukaryotic foreign gene and is replication defective. 
As a method of gene therapy, the present invention 
discloses a technique whereby a defective gene in a eukary- 
otic tissue may be replaced. This particular method com- 
30 prises inducing a mitotically-active state in the eukaryotic 
tissue to produce mitotically-active cells; preparing a retro- 
viral vector comprising a eukaryotic gene complementary to 
the defective gene in the eukaryotic tissue; and exposing the 
mitotically-active cells to the retroviral vector for a time 
35 period sufficient to allow incorporation of the gene of 
interest in the eukaryotic cell. By this method, the incorpo- 
ration of the gene of interest functions to replace the 
defective gene in the eukaryotic tissue. 
The present invention presents a revolutionary method for 
treating virtually any disease caused by a genetic deficiency 
in a eukaryote. Such is accomplished through the incorpo- 
ration of a non-defective gene complementary to the par- 
ticular deficiency in the diseased organism. More particu- 
larly, the incorporation of a particular complementary gene 
comprises a series of steps, wherein a mitotically-active state 
is first induced in the eukaryote cells, most preferably stem 
cells of the eukaryote. Thus, the general scheme of the 
technique, i.e., stimulating stem cell proliferation followed 
5o by retrovirus injection is postulated to provide a means to 
facilitate gene transfer into many different tissues. 
Applicants’ studies demonstrate the described foreign 
gene incorporation into mammalian adult skeletal muscle. 
Accordingly, from these studies, it is hypothesized similar 
55 gene incorporation may be accomplished in smooth muscle, 
gastrointestinal, brain, cardiac muscle, uterine, blood, skin 
or testicular tissue, especially those tissues as they exist in 
the human. 
W i n g  now to a consideration of the methods by which 
60 a mitotically-active state may be induced in a viable adult 
eukaryotic tissue or a eukaryotic cell culture, such a recep- 
tive state may be induced via any discomposition which 
induces cellular-repair mechanisms in a cell culture or 
tissue. As will be recalled, retroviruses are unable to insert 
65 genetic information into another cell unless that target cell is 
made receptive (i.e., mitotically active). A receptive state of 
a target cell may be induced by making the cell mitotically 
5 
40 
45 
5,466,676 
13 
active. A variety of techniques are available which induce 
such a mitotically-active state. By way of specific example, 
such includes the irradiation of the tissue or cell culture, the 
exposure of the cells or tissue to particular pharmaceutical 
agents, the physical agitation of a cell culture, or the surgical 
intrusion of a tissue, as well as through the vigorous exercise 
of a tissue. 
Among those pharmaceutical agents expected to be effec- 
tive in inducing the described mitotic or active state in cell 
culture or in vivo, the following list presents those agents 
most particularly preferred: collagenase, fibroblast growth 
factor, bupivacaine, estrogen and dexamethasone. 
The following tissue sectioning and staining protocol 
represents a method which may generally be used in the 
fixation of any type of tissue from any of a variety of animal 
species. Several experimental examples follow thereafter 
which are designed to illustrate particularly preferred 
embodiments of the inventions, both as they actually exist 
and as they are proposed to exist in the future (Le., prophetic 
exemplary use in treating genetic disease in humans). 
It should be appreciated that many modifications and 
changes can be made in the particular stimulatory agents and 
their doses, the particular retroviral construct (i.e., the pro- 
moter, the gene of interest, and the particular retrovirus) and 
the particular conditions under which the retrovirus intro- 
duced to a culture of cells or into a living adult tissue without 
departing from the spirit and scope of the invention. 
Tissue Sectioning and Staining 
Muscle sections were stained by the method of Dannen- 
berg and Suga.' Briefly, 16 um sections were mounted on 
0.5% gelatin slides and fixed 5-10 minutes at 4" C. with the 
same fixative as used in the dissection. The sections were 
washed briefly with PBS containing 2 mM MgCl, at 4" C. 
and once again for 10 minutes with the same solution. The 
sections were then washed for 10 minutes in PBS containing 
2 mM MgCl,, 0.01% sodium deoxycholate, and 0.02% 
Nonidet P40 at 4" C. The slides were briefly dried and 
stained for 18 hours at 37" C. in a PBS solution containing 
35 mM K,Fe(CN),, 35 mM K4Fe(CN),.3H,0, 2 mM 
MgCl,, 0.01% sodium deoxycholate, 0.02% Nonidet P4, 
and 1 mg/ml 5-bromo-4-chloro-3-indoyl-b-D-galactopyra- 
noside (Xgal). Following staining the slides were rinsed 
three times for 5 minutes each with PBS at room tempera- 
ture, blotted dry, and stained with 5% eosin. 
Applicants are in the process of replacing the P-galac- 
tosidase gene with the rat insulin-like growth factor I coding 
region, using the following strategy. The entire P-galactosi- 
dase gene was removed from the gag region of the retroviral 
"BAG" construct of Price, et al.? by restriction with Pvu I 
and BamHI. The insulin-like growth factor I coding region 
will be added to the gag site where P-galactosidase was 
removed as follows. Applicants were supplied with prIGF- 
Ib-42-a, a 422 bp insert in pUC-19, which included a partial 
5' untranslated region with 2 putative ATG translation start 
sites, the Pre, B, C ,  A, D and part of the E domains of the 
rat insulin like growth factor 1 coding region, without 
introns. The processed mature insulin-like growth factor I 
peptide did not contain the E domain. The 422-bp insulin- 
like growth factor I coding region was flanked by EcoRI 
restriction sites. 
BL-2 tissue culture facility 
An 80 ftz room was devoted solely to culture of the Psi2 
packing cell line and 3T3 cells, which were used to prove 
that the produced retrovirus is replication-incompetent, that 
is no recombinant wild-type retrovirus is produced. A BL-2 
rated laminar flow hood (Nuaire 425400) and a CO, 
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H,O-jacketed incubator (Nuaire) was also used in the . 
following studies. An Olympus CK2 inverted scope with 
phase contrast was available outside the culture facility. 
Laboratory facilities 
Two cryostats (IEC minotome) were available for pro- 
duction of tissue sections. An automatic microtome knife 
sharpener was also available for usage. Applicants' labora- 
tory has an Olympus BH-2 microscope with attached mOS 
color video camera so that a slide may be viewed simulta- 
neously through the binocular observation tube and on a 
video color monitor. This system is attached to a PC Vision 
Plus Frame Grabber Board in an AT-clone computer. Appli- 
cants have a JAVA image-processing program which permits 
the determination of relative area of indigo blue on a tissue 
section. 
Applicants' laboratory also contains apparatus for elec- 
trophoresis of agarose, sequencing and polyacrylamide gels, 
power supplies, microfuges, water baths, tissue homogeniz- 
ers, vacuum oven, sterilizer, freezers, gel dryers, pH meters, 
stirrers, IEC-5000 centrifuge, DNA sequencing apparatus, 
Geiger counters, recorders, pumps and electrical stimulators. 
Applicants have access to Departmental low and high cen- 
trifuges (Sorvall RC series to Beckman L5-50), gamma and 
beta scintillation counters, and Gilford spectrophotometer. 
EXAMPLES 
The following examples further illustrate certain features 
of particularly preferred methods as provided by the present 
invention. 
Example 1-Preparation of a Retroviral Construct 
The replication-defective retroviral construct is that of 
Price et a13 Psi2 cells producing the retrovirus containing the 
P-galactosidase and neomycin phosphotransferase genes 
(American Type Culture Collection CRL 9560) were grown 
to confluence in Dulbecos Modified Eagles Medium con- 
taining 10% fetal calf serum. The E. coli P-galactosidase 
gene used was under the promoter control of the retroviral 
Moloney murine leukemia virus 5' long-terminal repeat 
promoter region, and thus is constitutively expressed. The 
medium was withdrawn and replaced with fresh medium. 
Following three days of incubation, the retrovirus-contain- 
ing medium was collected, filtered through 0.45 um filters, 
brought to 8 ug/ml polybrene, and stored at -80" C. A titer 
of 2x10~  colony forming units (CFU) per milliliter was 
obtained, as determined by infection of NIH 3T3 cells. 
The retrovirus was tested for wild-type (replication-com- 
petent) viral particles by testing the ability of the condi- 
tioned media from infected NIH 3T3 cultures to produce a 
secondary infection in uninfected cells. No wild-type viral 
particles were detected, but as a precaution the retrovirus 
was handled in type IIB culture facilities. 
The retroviral construct was used in the experiments 
described in Examples 2 and 3. 
Example 2-In Vivo Foreign Gene Incorporation 
and Expression in Adult Female Rat Muscle 
The following experiment was designed to determine if a 
foreign gene could be successfully inserted and achieve 
expression in the tissue of a living animal employing a 
totally in vivo system. The experiment tests a method for 
inserting a vector which includes a foreign gene, in this case, 
the E. coli gene coding for P-galactosidase, into the existing 
DNA of skeletal muscle in adult rats. This system constitutes 
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an effective marker system to follow the incorporation of a 
gene of interest into a tissue. 
To maximize the probability of retroviral gene insertion, 
the retrovirus containing E. coli P-galactosidase gene was 
injected into the bupivacaine-damaged soleus muscle of the 
rat 24-48 hours following damage. 
In order to produce bupivacaine damage, the soleus 
muscles of 125 g female rats were exposed by lateral 
incisions. The left soleus muscle was injected bilaterally in 
each quarter with 0.3-0.5 ml 0.5% bupivacaine HCl, 0.1% 
methylparaben in isotonic NaCl (0.5% MarcaineQ Win- 
throp-Breon Labs) using a 27 g needle. There was consid- 
erable leakage of the liquid from the injection sites. The right 
soleus muscle served as the contralateral control and was 
similarly injected with 0.9% NaC1, 0.9% benzyl alcohol 
(bacteriostatic NaCl). 24-48 hours following bupivacaine 
damage, both left and right soleus muscles were again 
exposed and 0.3 ml of the retrovirus-containing medium was 
administered by injection in the same pattern as the bupiv- 
acaine and saline injections. The animals were then allowed 
to recover either 6 days or one month in a biohazard suite. 
Upon dissection, the soleus muscles were placed in a fresh 
solution of ice-cold 2% paraformaldehyde, 100 mM PIPES, 
2 mM MgCl,, 1.25 mM EGTA, pH 6.9, for 15 min. The 
tissue was then placed in an ice-cold PBS solution contain- 
ing 2 mM MgCl, and 30% sucrose for 3 hours. The muscles 
were blotted dry and embedded in OCT medium (Miles 
Laboratories) on dry ice. Embedded muscle was stored at 
-20” c. 
The contralateral soleus muscle received saline injections 
instead of bupivacaine, but otherwise was treated identically 
to the bupivacaine-damaged muscle. 
In all cases, injection of the retrovirus into the damaged 
soleus muscle resulted in the expression of histochemically 
detectable P-galactosidase activity in satellite cells and 
muscle fibers within the week following injection (FIG. 1). 
Furthermore, the expression was stable for at least one 
month following the injection of the retrovirus. Several tens 
of fibers were routinely found to express P-galactosidase 
activity in serial sections, though only a few fibers expressed 
the enzyme activity densely throughout the entire circum- 
ference of the fiber. In contrast, the contralateral control 
soleus muscle (which received saline instead of bupivacaine 
injections and was also injected with retrovirus) exhibited 
far less expression of P-galactosidase activity. (Table 1). 
Bupivacaine-damaged muscle that did not receive injections 
of retrovirus did not express P-galactosidase activity. 
Diffuse and Focal Foreign Gene Expression In Vivo 
Two patterns of P-galactosidase expression, diffuse and 
focal, were evident. Diffuse expression occurred within the 
circumference of a single fiber (FIG. 1, A and C). Often an 
adjacent fiber has a less dense expression of P-galactosidase 
activity within the fiber circumference; this apparent exclu- 
sivity of lineage was not a result of undamaged neighboring 
fibers because the phenomenon also occurred when the 
neighboring fibers were regenerating myotubes. Focal P-ga- 
lactosidase activity occurred immediately adjacent to the 
sarcolemma (FIG. 1 B and D) and occasionally in the 
intracellular matrix between fibers. Because this focal 
expression was maintained even after 1 month of regenera- 
tion, the structures associated with this expression might 
have been satellite cells or their daughter myonuclei. How- 
ever, because the apparent diffusible domain of a myo- 
nucleus overlapped several adjoining myonuclei, Applicants 
did not expect the expression of the P-galactosidase to be 
limited to within the myonuclear envelope. Nonetheless, at 
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the present time Applicants do not have an explanation for 
the mechanism underlying the specific patterns and variabil- 
ity of P-galactosidase expression in the regenerating skeletal 
muscle, and further do not wish to be limited to any such 
theory of gene expression in the presently described inven- 
tion. 
Applicants outlined a method to incorporate a single 
foreign gene into mammalian adult skeletal muscle that does 
not risk the possibility of immune rejection inherent in 
techniques involving the injection of infected myoblasts into 
an animal.” The technique introduced here opens the future 
possibility for the introduction of muscle-specific genes into 
muscle in vivo, followed by studies of altered muscle 
function and the control of muscle gene expression. 
The general scheme of the technique, i.e., stimulating 
stem cell proliferation followed by retrovirus injection, may 
provide a means to facilitate gene transfer into tissues other 
than muscle tissue. By way of example and not limitation, it 
is envisioned that the present retroviral mediated gene 
transfer system would be effective in such tissues as brain, 
intestinal tissue, cardiac tissue, skin, blood, testicular tissue 
and uterine tissue. 
TABLE 2 
P-galactosidase Expression 
bupivacaine-damaged control 
no. of muscles 
no. of samples 
8 5 
17 14 
0 (no stain) 0 I 
1 (light stain) 1 I 
2 (dark stain in serial sections) 16 0 
Fisher’s 1-tail test 
on proportions 
no. of successful trials 17* I 
*p<0.05 
Differential expression of retrovirally-transfected P-galactosidase activity in 
hupivacaine-damaged and undamaged soleus muscle. From each muscle at 
least one sample of ten to thirty 16 urn serial cross-sections were processed 
for the histochemical detection of P-galactosidase activity. The degree of 
P-galactosidase expression in each sample was scored according to the 
following system: 0, no activity; 1, occasional light diffuse or focal staining 
that does not necessarily appear in serial sections; 2, dark diffuse staining 
within the circumference of one or more fibers in serial sections. The Fisher’s 
1-tail test on proportions was performed (where scores of 1 and 2 were 
considered successful trials) and indicates a significantly greater P-galactosi- 
dase expression in the bupivacaine-damaged soleus muscle. 
Example 3-In Vivo Retroviral Gene Incorporation 
in Rat Uterine Tissue 
The following experiment was designed to examine the 
effectiveness of the presently described retroviral-mediated 
gene transfer system in mitotically-active uterine tissue of 
adult ovariectomized rats. Adult Sprague-Dawly female rats 
were ovariectomized under light ether anesthesia. The ani- 
mals were then allowed to recover for a period of 7 days. 
Following ovariectomy, the uterus of each animal was 
examined and found to have atrophied to the unstimulated 
state. The fully recovered ovariectomized rats with com- 
pletely atrophied uterine tissue were then injected with 
estrogen at a dose of about 40 micrograms per Kg body 
weight (40 ug/mg B.W.). Upon estrogenic stimulation, the 
uterine tissue began to regenerate, with the attendant 
increase in cell proliferation. 
Retroviral vectors including the P-galactosidase gene 
under the promoter control of the Moloney murine leukemia 
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virus (MuLV) 5' long-terminal repeat were then injected into 
the uterine cavity and allowed to bath in the estrogen-treated 
uterus. 
sacrificed. Uterine tissue samples were then fixed and exam- 
ined microscopically as described in Example 1. 
Results from this study indicate that the mitotically-active 
incorporated the P-galactosidase gene of the retroviral vec- 10 
tor. This study also suggests the use of other hormones, such 
as testosterone, prostaglandins, prolactin, follicle stimulat- 
ing hormone (FSH), human chorionic gonadotrophin (hCG), 
luteonizing hormone (LH), insulin, and other stimulatory 
hormones well known to those of skill in the art would be 15 
useful in the induction of a mitotically-active state in stimu- 
lating other cell types. 
Duranon with 
retrovims After a period of 18 hours, the treated animals were Expenmental design 
Groups 30day 180 day 
dyldy, mice without 8* 8 
bupivacaine-retrovirus 
retrovirus containing the coding 
regon of insdin-like growth 
factor I 
*Number of mice 
Chonology 
Day o: Injection of bupivacaine into soleus and anterior 
tibialis muscles 
Day 2: Injection of replication-incompetent MoMuLV 
with insulin-like growth factor I into the 2-day 
The treated designated muscles will then be removed and 
fixed as described previously. 
proliferating uterine cells of these adult female rats readily dyldy, mce with bupivacane- 8 8 
2o Marcaine damaged, recovering muscles. 
Retrovirus description and handling 
Example &Proposed Study for the In Vivo 
Regeneration of Dystrophic Muscle in Mice 
integration and expression of a foreign reporter gene, p-ga- coding region in the site in the multiple clodng 
lactosidase, in the replication-incompetent MoMuLV, into 25 region of p ~ 7 ~ 3 - 1 8  (Bethesda Research Laboratories). ne 
the DNA of replicating satellite cells of skeletal muscle in sma I site in the multiple region of p ~ ~ 3 - 1 8  and 
the dystrophic mouse. Applicants have already demonstrated IGF-I has been converted to a PvuI by Sigma linker #L2392. 
that the described interntion and expression Can be Applicants plan to convert the EcoRI site at the 3' end of 
achieved in adult normal rat skeletal muscle tissue, and insulk like growth factor I to a B& site by usage of 
therefore expect that the method Will be Successful in 30 & o M - x d  adaptor and B d - m  adaptor (New 
dYStrOPhiC mouse skeletal muscle tissue as well. This England Biolabs #1105 and 1106). Thus, the insulin-like 
hypothesis is s~pported in the literature from observations growth factor I coding region will then have a 5' p d  
that the regenerating capacity Of young adult dystrophic restriction, site and a 3' BamHI restriction. Recall that 
muscles is almost equal to that of nondystrophic  muscle^.'^ 35 P-galactosidase was removed by a 5' restriction at a PvuI site 
The ultimate application of the present methods in sup- and a 3' restriction at a BamHI site, into which the insulin- 
plying dystrophic tissue with a foreign gene is to employ the like growth factor I will be subcloned. 
method as a therapeutic corrective measure for the treatment The handling of the retrovirus, animal handling, and 
of animals with genetic diseases, such as muscular dystro- muscle sectioning are as described for Example 2. However, 
phy. In such an application, the retroviral vector will com- 4o staining procedures as described for Example 2 will differ 
prise a fragment of a dystrophin gene or a dystrophin gene because there is no P-galactosidase gene in this particular 
construct. replication-incompetent MoMuLV construct. 
In order to facilitate the inclusion of the required genetic The following analyses will be made on serial sections of 
information into a single retroviral vector, the dystrophin 
gene should comprise a dystrophin gene construct compris- 45 1. Identification of fibers expressing insulin-like growth 
ing a number of base pairs less than the 14,000 base pairs (14 factor 1 will be made by either: 
kb) of the native dystrophin gene. Most preferably, this a. In situ hybridization for insulin-like growth factor I 
dystrophin gene construct comprises between about mRNA, andor 
1O,O00-8,000 base pairs of the native dystrophin gene. In a b. Immunohistochemistry for neomycin phosphotrans- 
most preferred embodiment, the dystrophin gene construct 50 
comprises about 9,OOO base pairs of the native dystrophin 2. Sizes of fibers with positive identification of either 
gene. This particular gene construct comprises a protein insulin-like growth factor I -A, or neomycin phos- 
having a relative molecular weight of 200 Kd. photransferase vs size of fibers without expression in of 
Recent studies have found that a very mild dystrophic the aforementioned. 
phenotype was manifest in persons having only about 54% 55 In situ hybridization for insulin-like growth factor I 
of the native dystrophin protein". Thus, it is hypothesized mRNA will be performed, as described by Edwall, et aLZ5 
that significant deletions may be made in the native dystro- Applicants have obtained similar hybridization for the sense 
phin gene without a loss in essential biological function of and antisense probes for IGF-I and are increasing the 
the protein. Such a modified dystrophin gene is proposed for stringency to obtain preferential hybridization with the 
use in the dystrophin gene construct, as the "gene of 60 muscle IGF-I mRNA. For more specific localization of 
interest", in the proposed retroviral vector of the presently hybridization products, Applicants will employ 3H-labeled 
claimed methods for treating human muscular dystrophy. probes. 
PHASE I Biotinylated anti-neomycin phosphotransferase II will be 
The following experiment is designed to determine if the obtained from 5'-3' (#5307-621261). Applicants are using 
integration and expression of the coding region for the rat 65 biotinylated probes for in situ hybridization so there will be 
insulin-like growth factor-I peptide in fibers of dystrophic no difficulty with this detection system. 
muscle of mice will cause their hypertrophy. Neomycin phosphotransferase II is under constitutive 
In this experiment, propose to demonstrate the Applicants subcloned the insulin-like growth factor 1 
mwles :  
ferase II. 
5,466,676 
19 
expression by SV 40 early promoter region. Applicants have 
a JAVA image-processing software system which they use 
with a PC Vision Plus Frame Grabber Board in an AT-clone 
computer. Applicants use this system to determine the quan- 
tities of in situ hybridization, immunohistochemistry, and 
size of muscle fibers within serial sections. 
PHASE I1 
Retroviral vectors will be prepared which include a dys- 
trophin gene construct under the constitutive promoter con- 
trol of the MoLV 5’ long-terminal repeat. This dystrophin 
gene construct will comprise between about 10,000 and 
8,000 base pairs of the native dystrophin gene, and encode 
a dystrophin protein having a relative molecular weight of 
200,000. This particular gene fragment will be prepared as 
described by England et al?’ In a most preferred embodi- 
ment, the dystrophin gene construct will comprise about 
9,000 base pairs. 
Dystrophic muscle of mice will then be treated with 
bupivacaine, as described above. The tissue will then be 
exposed to the described dystrophin-construct containing 
retroviral vector. Excision, fixation and analysis of the 
treated tissue of the dystrophic animals will then be per- 
formed as described in the previous examples. 
Example 5-Proposed In Vivo Use in Human Gene 
Therapy of Muscular Degenerative Disease 
The gene encoding human dystrophin has been isolated as 
a “mammoth” gene, postulated to comprise 2.3 megabases. 
However, recent reports indicate the isolation of a segment 
of the native gene which has been demonstrated to impart to 
human subjects only mild dystrophic  phenotype^'^. Appli- 
cants propose the use of this “mini gene” together with the 
presently described and claimed retroviral mediated gene 
transfer system as applied to satellite muscle cells for the 
gene therapy of humans with genetic muscular degenerative 
diseases. These diseases include, by way of example, Duch- 
enne’s and Becker muscular dystrophies. 
Use of the retroviral-mediated gene transfer systems 
described by the Applicants will effectively eliminate cur- 
rently-recognized limitations in the art of gene therapy, such 
as the risk of immune rejection, diffusion, retroviral gene 
insert limitations and the requirement for multiple site 
injections (as in the case of myoblast injection to degenera- 
tive human muscle sites). 
While the determination of exact treatment regimens for 
such a therapy await human in vivo clinical trials, it is 
hypothesized that the same pharmaceutical agents, radiation 
treatments, hormones, and other cell or tissue-discomposing 
events would elicit a mitotically-active state in human tissue 
and cells as they have in Applicants’ experimental rats and 
mice. Current reviews suggest the process of muscle regen- 
eration in humans shows few significant differences from the 
processes in mammalian experiments, saving those of scale 
due to the large size of human muscles, nor is there currently 
any reason to believe that the control mechanisms of muscle 
regeneration differ to any significant degree5. Thus, the 
successful gene incorporation accomplished with the tech- 
niques provided and described herein in rats are expected to 
be mimicked for the successful gene incorporation in 
humans. 
The instant invention. has been disclosed in connection 
with specific embodiments. However, it will be apparent to 
those skilled in the art that variations from the illustrated 
embodiments may be undertaken without departing the spirit 
and scope of the invention. 
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What is claimed is: 
1. A method for enhancing incorporation of a foreign gene 
into a tissue and expressing the incorporated foreign gene 
comprising: 
inducing a mitotically-active state in a tissue in vivo to 
provide tissue with enhanced receptivity to the incor- 
poration of a foreign gene; 
preparing a retroviral vector capable of infecting a eucary- 
otic stem cell, said vector comprising a foreign gene; 
and 
injecting the tissue in vivo with the retroviral vector; 
wherein said method results in incorporation and expression 
of the gene. 
2. The method of claim 1, wherein the retroviral vector 
comprises a eucaryotic foreign gene. 
3. The method of claim 1, wherein the foreign is a 
prokaryotic gene. 
4. The method of claim 3, wherein the prokaryotic gene 
is a P-galactosidase gene. 
5. The method of claim 1, wherein the foreign gene is a 
eucaryotic gene within a replication defective retroviral 
vector. 
6. The method of claim 1 wherein a mitotically active 
state in a tissue is induced by treating the tissue with 
estrogen. 
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7. A method of retroviral injection into a tissue for the 12. The method of claim 11 wherein the murine leukemia 
incorporation of a gene in a tissue comprising: virus is Moloney murine leukemia virus. 
injecting the tissue with bupivacaine to induce a mitoti- 
injecting the mitotically active tissue with a retroviral 
13. The method of claim 7 wherein the foreign gene is a 
14. A method for incorporating and expressing a foreign 
cally active state; and 
vector including the gene: 
5 P-galactosidase gene. 
Y - I  
wherein said method provides efficient incorporation of the gene in a tissue comprising: 
gene in the tissue. 
tissue. 
inducing a mitotically-active state in a tissue in vivo; and 
injecting the tissue in vivo with a retroviral vector, said 
8. The method of claim 7 wherein the tissue is muscle 
lo 
9. The method of claim 7 wherein the tissue is uterine 
10. The method of claim 7 wherein the retroviral vector is 
11. The method of claim 10 wherein the retroviral vector l5 
retroviral vector including a foreign gene, 
wherein said foreign gene is efficiently incorporated in vivo tissue. 
replication defective. in the tissue. 
is a murine leukemia virus. * * * * *  
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